#USA #Minnetonka #NeuroBlate® #LITT #Monteris Medical

Groundbreaking Study on NeuroBlate® System for Epilepsy

In a substantial advancement for the treatment of drug-resistant epilepsy, Monteris Medical has announced the release of pioneering data from its NeuroBlate® system study, featured in JAMA Neurology. This represents the largest prospective analysis to date focusing on laser interstitial thermal therapy (LITT), emphasizing the technology's effectiveness and safety for treating the mesial temporal lobe epilepsy (MTLE).

The study utilized data from Monteris Medical's extensive LAANTERN research initiative, which encompasses over 1,000 patients across various institutions. Among the 145 individuals who participated in this pivotal study, the results demonstrated that LITT is a viable and minimally invasive alternative to traditional surgery without the extensive recovery time often associated with more invasive procedures.

Key Findings and Outcomes

The reported outcomes from this study were quite remarkable. The long-term analysis highlighted that over 58% of participants achieved seizure freedom, comparable to the traditional anterior temporal lobectomy (ATL) method. Specifically, 58.4% and 57.2% of patients reached Engel class 1 and International League Against Epilepsy (ILAE) class 1/2 seizure freedom, respectively, after one and two years. Patients also showed minimal readmission rates, while the procedure's nature allowed for quick recovery periods, with nearly all patients discharged the day after surgery.

In contrast to conventional surgical approaches, which require significant cranial opening and result in protracted rehabilitation, the NeuroBlate procedure employs a small incision that significantly reduces recovery times. Patients typically experience less pain and discomfort, often leaving the hospital within 24 hours, an appealing alternative for many.

Dr. Patrick Landazuri, a professor of neurology at the University of Kansas Medical Center and the lead author of the study, articulated the significance of these findings, stating, 'This study provides the most robust prospective data available, underscoring the effectiveness of LITT for treating drug-resistant MTLE. Our data indicates that patients not only enjoyed a high rate of seizure freedom, but they also exhibited an improved quality of life following the procedure, which is critical in the management of epilepsy.'

Implications for Future Treatment

Moreover, the potential application of this technique extends to both pediatric and adult populations, with results showing comparable benefits regardless of age group. It indicates that LITT is a promising technology for younger patients managing epilepsy, further reinforcing Monteris Medical’s commitment to enhancing patient outcomes. The study emphasized quality of life improvements were noted consistently, with over a third of patients either reducing or stopping their anti-seizure medications altogether following their treatment.

Additionally, advancements in robotics, such as the implementation of ROSA® robotics for cranial access, demonstrated increased surgical efficiency, marking an evolution in the operational procedures for epilepsy treatments.

Monteris Medical continues to pave the way for improved medical interventions in the field of neurology. As Martin J. Emerson, the president and CEO of Monteris Medical, stated, 'Our ongoing pursuit remains focused on developing innovative technology that profoundly enhances patient experiences and long-term outcomes. The findings from this notable study further solidify NeuroBlate’s position as a premier treatment option for those suffering from drug-resistant epilepsy.'

With LITT now standing alongside traditional surgeries in efficacy but outperforming them in recovery benefits, it presents a future filled with promise for countless epilepsy patients.

About the LAANTERN Study

The LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate® System, NCT02392078) study is the first multicenter laser ablation investigation designed to evaluate the NeuroBlate® system's performance and to provide real-world clinical evidence for its adoption in standard epilepsy care protocols. All procedures adhered to rigorous ethical standards, ensuring both patient safety and data integrity.

In conclusion, Monteris Medical is leading a transformative approach to treating epilepsy through its innovative NeuroBlate® system, offering hope and tangible results for many individuals who have previously faced limited options in managing their conditions.